Skip to main content

Table 2 Headache characteristics at baseline of the total cohort and the subgroups of patients suffering from migraine, tension-type headache (TTH), migraine and TTH and medication-overuse headache (MOH) and assignement to treatment modules

From: Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study

  Total Migraine TTH Migraine + TTH MOH
Number of patients 204 62 11 59 69
Duration of disease, Months, mean (SD) 240.4 ± 153.5 229.3 ± 151.7 141.8 ± 118.2 224.9 ± 137.2 279.8 ± 163.7
Headache frequency, days/month (SD) 14.5 ± 8.2 8.9 ± 4.3 15.3 ± 5.5 13.1 ± 7.5 19.6 ± 7.5
Intake frequency of attack-aborting medication, days/month (SD) 10.3 ± 7.3 6.7 ± 3.2 5.1 ± 3.5 6.9 ± 3.9 17.5 ± 7.3
Missed school-/workdays/3 month 24.6 ± 32.3 18.7 ± 18.9 16.3 ± 34.5 19.8 ± 20.7 35.2 ± 45.8
Experience with non-pharmacological treatment (%) 37.9 40.3 27.3 47.5 36.2
MIDAS, mean (SD) 51.94 ± 56.95 39.53 ± 35.89 43.1 ± 79.1 45.55 ± 46.22 70.53 ± 73.00
HADS-depression, mean (SD) 5.29 ± 3.90 4.34 ± 3.55 5.00 ± 5.64 5.29 ± 3.61 6.38 ± 3.99
HADS-anxiety, mean (SD) 7.02 ± 4.16 6.00 ± 3.33 5.67 ± 5.45 7.65 ± 3.93 7.83 ± 4.72
SF 12—physical (SD) 40.75 ± 8.63 41.64 ± 7.74 42.80 ± 9.98 43.02 ± 8.56 38.02 ± 8.45
SF 12—mental (SD) 44.34 ± 10.61 47.09 ± 9.45 46.55 ± 13.94 44.38 ± 10.88 41.67 ± 10.31